Biotech
New AmsterdamPharma
New AmsterdamPharma raises $453M Series at $2B valuation
$453M
Total Raised
Series
Latest Round
2019
Founded
120+
Employees
Amsterdam, Netherlands
1 min read
Quick Facts
Valuation
$2B
Latest Round Size
$453M
Latest Round Date
November 2024
New AmsterdamPharma: Series Funding Round
New AmsterdamPharma has successfully raised $453M in Series funding, reaching a valuation of $2B.
Company Overview
Developing novel cholesterol treatment drug for cardiovascular disease
Funding Details
The Series round was led by RA Capital, with participation from RTW Investments.
Company Information
- Headquarters: Amsterdam, Netherlands
- Founded: 2019
- Employees: 120+
- Category: Biotech
Investment
New AmsterdamPharma plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- RA Capital: Verified investor in Series
- RTW Investments: Verified investor in Series
Key Investors
RA Capital
Lead Investor
Verified investor in Series
RTW Investments
Investor
Verified investor in Series
About the Author
Editorial Team
Curated funding news from verified sources
Related Company Reports
Biotech
Orna Therapeutics
Orna Therapeutics Raises $251M Series B
Biotechnology company developing circular RNA therapeutics for cancer, genetic diseases, and infectious diseases
Emma Rodriguez
Oct 23, 2025
0 min read•$251M Series B
Biotech
Forge Biologics
Forge Biologics Raises $120M Series C
Gene therapy CDMO providing manufacturing and development services for AAV-based genetic medicines
Sarah Kim
Oct 23, 2025
0 min read•$120M Series C
Biotech
Vir Biotechnology
Vir Biotechnology Raises $250M
Clinical-stage immunology company developing treatments for infectious diseases including COVID-19, hepatitis B, and influenza
Sarah Kim
Oct 23, 2025
0 min read•$250M